Major Depressive Disorder in Adults

SECTION 1: Clinical Overview

1.1 Summary

Major Depressive Disorder (MDD) is a common, serious, and potentially life-threatening psychiatric condition characterized by persistent depressed mood and/or anhedonia accompanied by neurovegetative symptoms lasting at least two weeks. [1] MDD represents a syndrome of biological, psychological, and social dysfunction that profoundly impairs an individual's ability to function across all life domains—occupational, interpersonal, and self-care. The Global Burden of Disease Study 2019 identified MDD as the second leading cause of years lived with disability worldwide, affecting approximately 280 million people globally. [2]

The pathophysiology of MDD involves complex interactions between genetic vulnerability (heritability 35-40%), hypothalamic-pituitary-adrenal (HPA) axis dysregulation, monoamine neurotransmitter deficiency, reduced neurotrophic support (particularly Brain-Derived Neurotrophic Factor), neuroinflammation, and disrupted neural network connectivity. [3] These biological substrates interact with psychological vulnerabilities (negative cognitive schemas, rumination) and social stressors (loss, isolation, trauma) in a biopsychosocial model.

Diagnosis is clinical, based on DSM-5 or ICD-11 criteria, with validated screening instruments (PHQ-9) facilitating detection in primary care. The differential diagnosis is broad and includes bipolar disorder, persistent depressive disorder (dysthymia), adjustment disorder, grief reactions, substance-induced mood disorders, and mood disorders secondary to medical conditions (hypothyroidism, stroke, malignancy). [4]

Management follows a stepped-care model stratified by severity. Mild depression may respond to active monitoring and low-intensity psychological interventions. Moderate-to-severe depression requires pharmacotherapy (first-line: SSRIs) combined with evidence-based psychotherapy (CBT, IPT). Treatment-resistant cases benefit from switching antidepressant class, augmentation strategies (lithium, atypical antipsychotics), or neuromodulation (ECT, rTMS, esketamine). [5] Prognosis with adequate treatment is generally favorable, though recurrence rates are substantial (50% after one episode, 80% after two, 90% after three), necessitating maintenance therapy in recurrent cases. [6]

Suicide remains the most devastating complication, with lifetime suicide mortality of 4-7% in those hospitalized for MDD. Comprehensive suicide risk assessment and safety planning are mandatory components of care. [7]

1.2 Key Facts

1.3 Clinical Pearls

Diagnostic Pearl: "The Core Dyad" Diagnosis requires at least one of: (1) depressed mood OR (2) anhedonia. Neither alone is sufficient without the other plus additional symptoms. Anhedonia—the inability to experience pleasure even from previously enjoyed activities—has higher specificity for MDD and predicts better response to biological treatments. [3]

Screening Pearl: "PHQ-2 then PHQ-9" The two-item PHQ-2 (depressed mood + anhedonia) has 97% sensitivity for detecting MDD. A positive screen (score ≥3) should trigger full PHQ-9 completion. This sequential approach optimizes clinical efficiency. [14]

Treatment Pearl: "Start Low, Go Slow, But Go" Initiate SSRIs at standard starting doses (sertraline 50mg, escitalopram 10mg). Therapeutic effect requires 2-4 weeks at adequate dose. If partial response at 4-6 weeks, titrate to maximum tolerated dose before switching. Premature switching is the most common prescribing error. [15]

Safety Pearl: "The Therapeutic Lag Paradox" Physical energy and motivation often improve before mood lifts (typically by week 1-2). This "therapeutic window" paradoxically increases suicide risk as patients regain capacity to act on persistent suicidal thoughts. Enhanced monitoring during weeks 2-4 is critical. [16]

Diagnostic Pitfall: "The Bipolar Trap" Always screen for prior manic/hypomanic episodes before initiating antidepressants. The Mood Disorder Questionnaire (MDQ) screens for bipolar disorder. SSRI monotherapy in undiagnosed bipolar disorder can trigger manic switch (10-15% risk) or rapid cycling, worsening long-term prognosis. [17]

Exam Mnemonic: "SIG E CAPS" (Prescribe Energy Capsules) Sleep disturbance, Interest decreased (anhedonia), Guilt/worthlessness, Energy decreased, Concentration impaired, Appetite change, Psychomotor change, Suicidal ideation. This covers the nine DSM-5 criteria efficiently for examinations. [1]

Elderly Pearl: "Depression vs. Dementia" In elderly patients presenting with cognitive complaints: Depression (pseudodementia) features rapid onset, "I don't know" responses, preserved attention to orientation, and subjective distress about deficits. Dementia features insidious onset, confabulation, disorientation, and lack of insight. Depression-related cognitive impairment is reversible with treatment. [18]

Severity Pearl: "The Melancholic Phenotype" Melancholic features (complete anhedonia, diurnal variation with morning worsening, early morning awakening, psychomotor disturbance, excessive guilt, weight loss) predict superior response to biological treatments (antidepressants, ECT) versus psychotherapy alone. [1]

1.4 Why This Matters Clinically

Patient Outcomes: Untreated depression leads to "kindling"—a neurobiological phenomenon where each episode lowers the threshold for subsequent episodes and increases treatment resistance. Early, adequate treatment prevents this progressive deterioration. Suicide is the 10th leading cause of death overall and the 2nd leading cause in ages 15-34. [7]

Healthcare Burden: MDD costs the global economy over $1 trillion annually in lost productivity and healthcare expenditure. In the UK, depression accounts for 70 million lost working days annually. The WHO predicts depression will become the leading cause of disability by 2030. [2]

Medico-Legal Considerations: Suicide risk assessment documentation is one of the most scrutinized areas in medical malpractice litigation. Every clinical encounter with a depressed patient requires documented assessment of suicidal ideation, intent, plan, access to means, and protective factors. Failure to assess or document appropriately creates significant liability exposure. [19]

Examination Relevance: MDD appears in every major medical examination (MRCP, USMLE, PLAB, MRCPsych). High-yield areas include DSM-5 criteria, PHQ-9 interpretation, SSRI pharmacology, serotonin syndrome recognition, suicide risk stratification, and ECT indications.

---

SECTION 2: Epidemiology

2.1 Incidence and Prevalence

Global Epidemiology:

• Point Prevalence: 4.4% globally (322 million people affected) [2]
• 12-Month Prevalence: 7.1% US adults, 6.9% European adults [8]
• Lifetime Prevalence: 16.6% (US), 10-20% internationally [9]
• Incidence: Annual incidence 3.0% in women, 1.8% in men [10]

Temporal Trends:

• 18.4% increase in global prevalence from 2005-2015 [2]
• COVID-19 pandemic associated with 25% increase in depression prevalence globally [20]
• Concerning increase in adolescent and young adult depression over past 15 years

Geographic Variation:

• Higher reported rates in high-income countries (likely reflecting diagnostic access)
• Highest disease burden in low-middle income countries (due to treatment gap)
• Seasonal Affective Disorder (SAD) shows winter peak at northern latitudes

Healthcare Burden:

• 2nd leading cause of years lived with disability (YLDs) globally [2]
• Accounts for 10% of all non-fatal disability burden
• 50% of patients with MDD never receive treatment (treatment gap) [2]

2.2 Demographics Table

2.3 Risk Factor Tables

Non-Modifiable Risk Factors:

Modifiable Risk Factors:

2.4 Protective Factors

---

SECTION 3: Pathophysiology

3.1 Etiology Overview: The Biopsychosocial Model

MDD arises from complex interactions between biological vulnerability, psychological factors, and social/environmental stressors. No single etiological factor is sufficient; rather, MDD represents a "final common pathway" of multiple converging mechanisms. [3]

Genetic Factors (35-40% heritability):

• Twin studies demonstrate concordance of 37% (monozygotic) vs. 18% (dizygotic)
• Genome-wide association studies identify > 100 risk loci, each with small effect
• Key genes implicated: SLC6A4 (serotonin transporter), BDNF, FKBP5, CRHR1
• Gene-environment interactions crucial: 5-HTTLPR polymorphism moderates impact of early adversity

Epigenetic Mechanisms:

• Childhood adversity produces lasting epigenetic modifications
• Hypermethylation of glucocorticoid receptor (NR3C1) gene promoter
• Altered stress response persists into adulthood
• These changes are potentially reversible with treatment

3.2 The Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

The HPA axis is the body's central stress response system, and its dysregulation is one of the most replicated findings in MDD. [3]

Normal Stress Response:

1. Stressor perceived → Amygdala activation
2. Hypothalamus releases Corticotropin-Releasing Hormone (CRH)
3. CRH stimulates anterior pituitary to release ACTH
4. ACTH stimulates adrenal cortex to release cortisol
5. Cortisol provides negative feedback to hypothalamus/pituitary (terminating response)

Pathological Changes in MDD:

• Glucocorticoid Receptor Resistance: Chronic stress leads to downregulation of GR in hippocampus and hypothalamus
• Failed Negative Feedback: Elevated cortisol fails to suppress CRH/ACTH release
• Chronic Hypercortisolemia: Sustained cortisol elevation is neurotoxic
• Dexamethasone Suppression Test: 50% of melancholic patients fail to suppress cortisol following dexamethasone

Clinical Correlates:

• Hypercortisolemia correlates with depression severity
• Explains insomnia (cortisol disrupts sleep architecture)
• Explains hippocampal atrophy (cortisol is neurotoxic to hippocampal neurons)
• Normalization of HPA axis predicts sustained remission

3.3 The Monoamine Hypothesis

The monoamine hypothesis remains foundational, though now understood as reflecting downstream consequences rather than primary causation. [3]

Core Premise:

• Depression results from functional deficiency of monoamine neurotransmitters: serotonin (5-HT), norepinephrine (NE), and dopamine (DA)
• Antidepressants increase monoamine availability → clinical improvement

Evidence Supporting:

• Reserpine (depletes monoamines) → causes depression
• Monoamine oxidase inhibitors (prevent monoamine breakdown) → antidepressant
• SSRIs/SNRIs (block reuptake) → antidepressant
• Tryptophan depletion → transient mood lowering in remitted patients

Specific Neurotransmitter Roles:

Limitations of Monoamine Hypothesis:

• Monoamine levels increase within hours; clinical effect takes weeks
• 30-40% of patients do not respond to monoaminergic drugs
• No consistent evidence of baseline monoamine deficiency in depressed patients

3.4 The Neurotrophic Hypothesis

Modern understanding emphasizes neuroplasticity and neurotrophic factor dysregulation as central to MDD pathophysiology. [3]

Brain-Derived Neurotrophic Factor (BDNF):

• BDNF is essential for neuronal survival, dendritic arborization, synaptic plasticity, and neurogenesis
• Serum BDNF levels are reduced in MDD and correlate with depression severity
• Postmortem studies show reduced BDNF in hippocampus and PFC of depressed individuals

Mechanism of BDNF Reduction:

1. Chronic stress → elevated cortisol
2. Cortisol suppresses BDNF gene transcription
3. Reduced BDNF → dendritic spine retraction, reduced synaptogenesis
4. Hippocampal and prefrontal volume reduction
5. Impaired emotional regulation and cognitive function

Neuroplasticity Effects:

• Hippocampal volume reduction (10-15% in recurrent MDD)
• Prefrontal cortical thinning
• Reduced synaptic density
• These changes are partially reversible with treatment (antidepressants increase BDNF)

Therapeutic Implications:

• Antidepressants increase BDNF expression (explains therapeutic lag)
• Ketamine rapidly increases BDNF and synaptogenesis
• Exercise is a potent BDNF inducer

3.5 Neuroinflammation and Immune Dysregulation

Depression is increasingly understood as a systemic inflammatory condition with prominent central immune activation. [21]

Evidence for Inflammation:

• Elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, CRP) in 30-50% of MDD patients
• Meta-analyses confirm effect sizes of d=0.5-0.7 for cytokine elevations
• Anti-inflammatory treatments show antidepressant effects in trials
• Medical conditions with high inflammation (autoimmune, cardiovascular) have high depression comorbidity

Mechanisms of Inflammation-Induced Depression:

1. Kynurenine Pathway Activation:

   • Inflammatory cytokines activate indoleamine 2,3-dioxygenase (IDO)
   • Tryptophan shunted from serotonin synthesis toward kynurenine
   • Results in: (a) reduced serotonin, (b) increased quinolinic acid (neurotoxic NMDA agonist)

2. Microglial Activation:

   • Microglia shift from surveying to pro-inflammatory phenotype
   • Release cytokines, reactive oxygen species
   • Impair synaptic pruning and neuroplasticity

3. Blood-Brain Barrier Disruption:

   • Peripheral cytokines access CNS
   • Activates central inflammatory cascades

Clinical Correlates:

• Treatment-resistant depression associated with higher inflammatory markers
• Anti-inflammatory augmentation may benefit inflammatory subtype
• Exercise and Mediterranean diet reduce inflammation

3.6 Neural Circuit Dysregulation

Functional neuroimaging reveals disrupted connectivity in specific neural networks in MDD. [3]

Key Networks Affected:

Specific Regional Abnormalities:

• Prefrontal Cortex: Reduced activity in dorsolateral PFC (executive function)
• Amygdala: Hyperactive in response to negative stimuli; persistent after stimulus offset
• Hippocampus: Volume reduction; impaired contextual memory and emotional regulation
• Anterior Cingulate Cortex: Altered activity; involved in emotional processing and pain

3.7 Classification and Staging

DSM-5 Severity Specifiers:

DSM-5 Specifiers:

Course Specifiers:

• Single Episode: First lifetime episode
• Recurrent: ≥2 episodes with ≥2 months remission between
• In Partial Remission: Residual symptoms; full criteria not met
• In Full Remission: No significant symptoms for ≥2 months

---

SECTION 4: Clinical Presentation

4.1 DSM-5 Diagnostic Criteria

Criterion A: Five or more of the following symptoms present during the same 2-week period, representing a change from previous functioning. At least one symptom is either (1) depressed mood or (2) loss of interest or pleasure.

Criterion B: Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Criterion C: Episode not attributable to physiological effects of a substance or another medical condition.

Criterion D: Not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified/unspecified schizophrenia spectrum disorders.

Criterion E: There has never been a manic or hypomanic episode (unless substance-induced or attributable to another medical condition).

4.2 Symptom Details

4.3 Signs on Examination

4.4 Atypical and Special Presentations

Atypical Depression (DSM-5 specifier):

• Mood reactivity (can be cheered up temporarily)
• Hypersomnia (> 10 hours/day)
• Hyperphagia/weight gain
• Leaden paralysis
• Interpersonal rejection sensitivity

Masked/Somatized Depression:

• Primary presentation with physical symptoms
• Chronic pain, fatigue, GI symptoms, headache
• Denial of psychological symptoms
• More common in elderly, certain cultures

Psychotic Depression:

• Mood-congruent delusions (guilt, poverty, nihilism, somatic)
• Cotard syndrome (belief that one is dead or organs are rotting)
• Auditory hallucinations (derogatory voices)
• Requires antipsychotic + antidepressant OR ECT

Depression with Anxious Distress:

• Feeling keyed up or tense
• Feeling unusually restless
• Difficulty concentrating due to worry
• Fear that something awful may happen
• Feeling of loss of control
• Poorer treatment response; higher suicide risk

4.5 Red Flags

---

SECTION 5: Suicide Risk Assessment

5.1 Epidemiology of Suicide in MDD

• Lifetime suicide mortality in MDD: 4-7% (hospitalized patients); 2-4% (outpatients) [7]
• Suicide attempts: 10-15% of MDD patients will attempt suicide
• Suicidal ideation: Present in 50-60% of MDD patients at some point
• Completed suicide ratio: 25:1 attempts to completions (overall); 3:1 in elderly men

5.2 Risk Stratification Framework

Acute Risk Factors (Modifiable):

Chronic Risk Factors (Static):

Protective Factors:

• Reasons for living (children, responsibilities)
• Religious/cultural beliefs against suicide
• Strong social support
• Therapeutic alliance
• Limited access to means
• Fear of death/pain
• Future orientation (plans, goals)

5.3 Structured Assessment Tools

Columbia Suicide Severity Rating Scale (C-SSRS):

• Gold standard for suicide assessment in research and clinical practice
• Assesses ideation severity, intensity, and behavior
• Categorizes ideation intensity (1-5 scale)
• Documents specific suicide attempts with details

Questions to Ask:

1. "Have you had thoughts of being better off dead, or of hurting yourself?"
2. "Have you actually had thoughts of killing yourself?"
3. "Have you thought about how you might do this?"
4. "Have you had any intention of acting on these thoughts?"
5. "Have you done anything to prepare?" (Obtained means, written note, said goodbyes)

PHQ-9 Item 9:

• "Thoughts that you would be better off dead, or of hurting yourself"
• Any positive response requires further assessment
• Score of 1+ triggers clinical risk assessment

5.4 Documentation Requirements

Every encounter with a depressed patient should document:

5.5 Safety Planning

Stanley-Brown Safety Planning Intervention:

1. Warning signs: Personal triggers and symptoms of crisis
2. Internal coping strategies: What patient can do alone to distract/calm
3. Social contacts for distraction: People and places that provide positive distraction
4. People to ask for help: Specific individuals who can provide support in crisis
5. Professional resources: Therapist, psychiatrist, crisis line, ED
6. Means restriction: Specific plan to reduce access to lethal means

---

SECTION 6: Differential Diagnosis

6.1 Psychiatric Differential Diagnosis

6.2 Medical Differential Diagnosis

6.3 Medication-Induced Depression

---

SECTION 7: Investigations

7.1 Routine Baseline Investigations

7.2 Targeted Investigations

7.3 Neuroimaging

7.4 Pre-Treatment ECG

Indications:

• Baseline before starting antidepressant with QTc risk (citalopram, escitalopram > 20mg, TCAs)
• Personal or family history of cardiac disease
• Age > 65 years
• Concurrent QTc-prolonging medications

QTc Thresholds:

• Normal: less than 450ms (men), less than 460ms (women)
• Borderline: 450-470ms (men), 460-480ms (women)
• Prolonged: > 470ms (men), > 480ms (women)
• Avoid citalopram/escitalopram if QTc > 500ms

---

SECTION 8: Screening and Assessment Instruments

8.1 Patient Health Questionnaire-9 (PHQ-9)

Description: 9-item self-report questionnaire based on DSM-IV criteria, validated for DSM-5. Gold standard for depression screening in primary care. [14]

Scoring:

• Each item scored 0-3 (Not at all → Nearly every day)
• Total score range: 0-27

Psychometric Properties:

• Sensitivity: 88% (at cutoff ≥10)
• Specificity: 88% (at cutoff ≥10)
• Positive Predictive Value: 57%
• Negative Predictive Value: 98%

Item 9 (Suicidal Ideation):

• Any score ≥1 requires clinical risk assessment
• "Thoughts that you would be better off dead, or of hurting yourself in some way"

8.2 PHQ-2 Screening

Items:

1. "Little interest or pleasure in doing things"
2. "Feeling down, depressed, or hopeless"

Scoring: 0-6 total; score ≥3 is positive screen (triggers full PHQ-9)

Performance:

• Sensitivity: 97% for MDD
• Specificity: 67%
• Recommended as first-step screening in all patients

8.3 Hamilton Depression Rating Scale (HAM-D/HDRS)

Description: 17-item clinician-administered scale. Gold standard for clinical trials.

Scoring:

• 0-7: Normal
• 8-13: Mild depression
• 14-18: Moderate depression
• 19-22: Severe depression
• ≥23: Very severe depression

Use: Research, monitoring treatment response in specialty settings. 50% reduction in HAM-D score = treatment response.

8.4 Other Validated Instruments

---

SECTION 9: Management

9.1 Principles of Treatment

Goals of Treatment:

1. Response: ≥50% reduction in symptom severity
2. Remission: Minimal or no residual symptoms (PHQ-9 less than 5, HAM-D less than 7)
3. Recovery: Sustained remission ≥4-6 months
4. Prevention of relapse: Maintain gains during continuation phase
5. Prevention of recurrence: Long-term prevention in recurrent MDD

Treatment Phases:

9.2 Stepped Care Algorithm

┌─────────────────────────────────────────────────────────────────────────┐
│                    ADULT DEPRESSION MANAGEMENT ALGORITHM                 │
│                           (NICE NG222 / APA Based)                       │
└─────────────────────────────────────────────────────────────────────────┘
                                      │
                                      ▼
                    ┌─────────────────────────────────┐
                    │      INITIAL ASSESSMENT          │
                    │  • Confirm diagnosis (DSM-5)    │
                    │  • PHQ-9 score + severity       │
                    │  • SUICIDE RISK ASSESSMENT      │
                    │  • Rule out bipolar (MDQ)       │
                    │  • Rule out medical causes      │
                    │  • Assess functional impairment │
                    └─────────────────────────────────┘
                                      │
                    ┌─────────────────┼─────────────────┐
                    ▼                 ▼                 ▼
          ┌─────────────────┐  ┌─────────────────┐  ┌─────────────────┐
          │  MILD (PHQ 5-9) │  │ MODERATE (10-19)│  │ SEVERE (≥20)    │
          │                 │  │                 │  │ OR PSYCHOTIC    │
          └────────┬────────┘  └────────┬────────┘  └────────┬────────┘
                   │                    │                    │
                   ▼                    ▼                    ▼
          ┌─────────────────┐  ┌─────────────────┐  ┌─────────────────┐
          │ STEP 1:         │  │ STEP 2:         │  │ STEP 3:         │
          │ • Active        │  │ • SSRI + HIGH-  │  │ • Urgent Psych  │
          │   monitoring    │  │   INTENSITY     │  │   referral      │
          │ • Psychoeducat- │  │   PSYCHOTHERAPY │  │ • Consider      │
          │   ion           │  │   (CBT or IPT)  │  │   hospitalizat- │
          │ • Guided self-  │  │ • OR Antidepres-│  │   ion           │
          │   help          │  │   sant alone    │  │ • Pharmacother- │
          │ • Exercise      │  │   (shared       │  │   apy + therapy │
          │ • Behavioral    │  │   decision)     │  │ • +Antipsychot- │
          │   activation    │  │                 │  │   ic if         │
          │ • Review 2-4    │  │                 │  │   psychotic     │
          │   weeks         │  │                 │  │                 │
          └────────┬────────┘  └────────┬────────┘  └────────┬────────┘
                   │                    │                    │
          ┌────────▼────────┐  ┌────────▼────────┐  ┌────────▼────────┐
          │   RESPONSE?     │  │   RESPONSE BY   │  │   RESPONSE?     │
          │   (2-4 weeks)   │  │   4-6 WEEKS?    │  │   (4-6 weeks)   │
          └────────┬────────┘  └────────┬────────┘  └────────┬────────┘
               Yes │ No            Yes │ No            Yes │ No
                   │                   │                   │
                   ▼                   ▼                   ▼
          ┌─────────────────┐  ┌─────────────────┐  ┌─────────────────┐
          │ Continue or     │  │ Optimize:       │  │ TREATMENT       │
          │ graduate to     │  │ • Increase dose │  │ RESISTANT:      │
          │ Step 2 if       │  │ • Ensure        │  │ • ECT (1st      │
          │ persists        │  │   adherence     │  │   choice if     │
          │                 │  │ • Address       │  │   severe)       │
          │                 │  │   comorbidity   │  │ • Esketamine    │
          │                 │  │                 │  │ • Lithium       │
          │                 │  │ If no response: │  │   augmentation  │
          │                 │  │ • Switch SSRI   │  │ • Atypical      │
          │                 │  │ • Switch class  │  │   antipsychotic │
          │                 │  │   (SNRI, TCA)   │  │   augmentation  │
          │                 │  │ • Augment (Li+, │  │ • rTMS          │
          │                 │  │   aripiprazole) │  │ • VNS/DBS       │
          └─────────────────┘  └─────────────────┘  └─────────────────┘
                                      │
                                      ▼
                    ┌─────────────────────────────────┐
                    │        CONTINUATION PHASE        │
                    │  • Maintain effective treatment │
                    │    for 6-12 months after        │
                    │    remission                    │
                    │  • Same dose that achieved      │
                    │    remission                    │
                    │  • Monitor for relapse          │
                    └─────────────────────────────────┘
                                      │
                                      ▼
                    ┌─────────────────────────────────┐
                    │        MAINTENANCE PHASE         │
                    │  • Consider lifelong Rx if:     │
                    │    - ≥3 prior episodes          │
                    │    - 2 episodes + risk factors  │
                    │    - Severe or chronic episodes │
                    │  • Gradual taper (25%/month)    │
                    │    if discontinuing             │
                    └─────────────────────────────────┘

9.3 Pharmacological Management

9.3.1 First-Line Antidepressants: SSRIs

SSRIs are first-line due to favorable efficacy-to-side-effect ratio, safety in overdose, and once-daily dosing. [4]

Mechanism of Action:

• Selectively inhibit serotonin (5-HT) reuptake transporter (SERT)
• Increase synaptic 5-HT availability
• Downstream effects: receptor desensitization, BDNF upregulation, neurogenesis
• Therapeutic effect requires 2-4 weeks (receptor and neuroplastic changes)

SSRI Comparison Table:

SSRI Side Effects:

9.3.2 Second-Line Antidepressants

9.3.3 Augmentation Strategies

For partial response after adequate trial (≥8 weeks at therapeutic dose):

9.3.4 Treatment-Resistant Depression (TRD)

Definition: Failure to respond to ≥2 adequate antidepressant trials (different classes, adequate dose, 6-8 weeks each). [15]

Evaluation:

1. Confirm diagnosis (rule out bipolar, medical causes)
2. Assess adherence
3. Optimize current treatment
4. Address comorbidities (substance use, personality disorder, anxiety)
5. Consider pharmacogenomic testing

TRD Treatment Options:

9.4 Electroconvulsive Therapy (ECT)

ECT remains the most effective treatment for severe depression and is the gold standard for treatment-resistant depression. [13]

Mechanism:

• Controlled induction of generalized seizure under anesthesia
• Increases BDNF, promotes neuroplasticity
• Modulates neurotransmitter systems
• Resets HPA axis function
• Precise mechanism unknown but efficacy well-established

Indications:

• Severe depression with psychotic features
• Severe depression with catatonia
• High suicide risk requiring rapid response
• Food/fluid refusal with medical compromise
• Treatment-resistant depression (failed ≥2 medication trials)
• Prior positive response to ECT
• Pregnancy (safer than some medications)
• Medical frailty precluding medications

Contraindications:

• Absolute: Recent MI (less than 3 months), recent stroke, intracranial mass with increased ICP
• Relative: Severe pulmonary disease, unstable angina, retinal detachment, pregnancy (not absolute)

Procedure:

1. Pre-procedure fasting (NPO 8 hours)
2. IV access, ECG monitoring, pulse oximetry, BP
3. Short-acting anesthetic (propofol, methohexital, etomidate)
4. Muscle relaxant (succinylcholine)
5. Bite block insertion
6. Electrode placement (bilateral or unilateral)
7. Brief-pulse electrical stimulus (typically 0.5-2 seconds)
8. Induced seizure (target 20-60 seconds motor; 25-120 seconds EEG)
9. Recovery and monitoring

Treatment Course:

• Acute: 6-12 sessions (typically 3x weekly)
• Continuation: Weekly → biweekly → monthly
• Maintenance: Monthly sessions for relapse prevention

Side Effects:

Efficacy:

• Response rate: 50-70% in TRD
• Remission rate: 35-50%
• Faster response than medication (often within 1-2 weeks)
• Superior to medication in severe, psychotic, and catatonic depression

9.5 Psychotherapy

9.5.1 Cognitive Behavioral Therapy (CBT)

CBT is the most extensively studied and evidence-based psychotherapy for depression. [12]

Theoretical Framework:

• Depression maintained by negative cognitive patterns
• Beck's cognitive triad: negative views of self, world, and future
• Cognitive distortions: all-or-nothing thinking, catastrophizing, mind-reading, should statements
• Behavioral component: reduced positive reinforcement due to withdrawal/inactivity

Key Techniques:

1. Behavioral Activation: Scheduling pleasurable and mastery activities
2. Cognitive Restructuring: Identifying and challenging negative automatic thoughts
3. Behavioral Experiments: Testing beliefs through real-world experiments
4. Thought Records: Documenting situations, thoughts, emotions, alternative thoughts
5. Problem-Solving: Structured approach to addressing life problems
6. Graded Task Assignment: Breaking overwhelming tasks into manageable steps

Treatment Parameters:

• Duration: 12-20 sessions (typically weekly)
• Format: Individual (most evidence), group (cost-effective), computerized (iCBT)
• Delivered by: Trained therapists (psychologists, counselors, CBT therapists)

Efficacy:

• Comparable to antidepressants for mild-moderate depression
• Combined treatment superior for severe depression
• Lower relapse rates than medication alone after treatment ends
• Effect size: d = 0.6-0.8 vs. control

9.5.2 Other Evidence-Based Psychotherapies

9.6 Other Treatments

9.6.1 Repetitive Transcranial Magnetic Stimulation (rTMS)

• Non-invasive neuromodulation using magnetic pulses
• FDA-approved for TRD (2008)
• Targets left dorsolateral prefrontal cortex (DLPFC)
• Sessions: 20-30 daily sessions over 4-6 weeks
• Response rate: 30-50%; remission 15-30%
• Minimal side effects (scalp discomfort, headache)
• Newer protocols: theta-burst (shorter sessions), accelerated (multiple daily sessions)

9.6.2 Intranasal Esketamine (Spravato)

• S-enantiomer of ketamine; NMDA receptor antagonist
• FDA-approved for TRD (2019) and MDD with suicidal ideation (2020)
• Mechanism: rapid glutamatergic effects; BDNF release; synaptogenesis
• Administration: Supervised nasal spray (56mg or 84mg); twice weekly initially, then weekly/biweekly
• Requires 2-hour observation due to dissociative effects, sedation, BP elevation
• Response often seen within hours to days
• REMS program required (registration, monitoring)

9.6.3 Light Therapy

• First-line for Seasonal Affective Disorder (SAD)
• 10,000 lux bright light for 30 minutes each morning
• Onset of action: 1-2 weeks
• Side effects: Headache, eye strain (rare)
• May augment antidepressants in non-seasonal depression

9.6.4 Exercise

• Evidence equivalent to antidepressants for mild-moderate depression
• Mechanism: BDNF upregulation, endorphin release, anti-inflammatory effects
• Prescription: Moderate-intensity aerobic exercise, 30-45 minutes, 3-5x weekly
• Benefits beyond depression: cardiovascular health, metabolic health, sleep

---

SECTION 10: Special Populations

10.1 Elderly Depression (Late-Life Depression)

Epidemiology: 15-20% of elderly community dwellers; 30-45% in nursing homes

Special Considerations:

• Presentation: More somatic complaints, cognitive symptoms, anxiety, less expressed sadness
• "Pseudodementia": Depression-related cognitive impairment mimics dementia (but is reversible)
• Vascular depression: Associated with cerebrovascular disease and executive dysfunction
• Comorbidity: Medical illness, polypharmacy, social isolation, bereavement

Assessment:

• Geriatric Depression Scale (GDS-15) validated for this population
• Screen for cognitive impairment (MoCA, MMSE)
• Medical workup: TSH, B12, metabolic panel, consider neuroimaging

Treatment Modifications:

• "Start low, go slow, but go": Lower starting doses but titrate to full therapeutic doses
• SSRIs preferred (sertraline, escitalopram, citalopram max 20mg)
• Avoid anticholinergic drugs (TCAs, paroxetine)
• ECT is safe and highly effective in elderly
• Address psychosocial factors: isolation, loss, role changes

10.2 Perinatal Depression

Epidemiology:

• Prenatal depression: 10-15%
• Postpartum depression: 10-15% (peak 4-6 weeks postpartum)
• Postpartum psychosis: 0.1-0.2% (medical emergency)

Screening: Edinburgh Postnatal Depression Scale (EPDS) at prenatal and postnatal visits

Treatment in Pregnancy:

• Untreated depression itself carries risks (preterm birth, low birth weight, bonding)
• SSRIs generally considered acceptable (sertraline preferred)
• Paroxetine avoided in first trimester (cardiac defects)
• ECT safe and effective
• Psychotherapy (CBT, IPT) first-line for mild-moderate

Treatment in Breastfeeding:

• Sertraline: Low milk transfer, minimal infant serum levels (preferred)
• Paroxetine: Low milk transfer
• Fluoxetine: Higher transfer, long half-life (caution)

Postpartum Psychosis:

• Psychiatric emergency requiring immediate hospitalization
• Screen for infanticide risk
• Treatment: Antipsychotic + mood stabilizer (often becomes bipolar diagnosis)

10.3 Depression with Comorbid Medical Illness

Cardiovascular Disease:

• Depression is independent risk factor for MI and mortality
• Sertraline is safest post-MI (SADHART trial)
• Avoid TCAs (cardiotoxic)

Diabetes:

• Bidirectional relationship; each doubles risk of the other
• Depression impairs diabetes self-care
• SSRIs may improve glycemic control

Chronic Pain:

• High comorbidity; shared pathophysiology
• Duloxetine, TCAs effective for both

Cancer:

• Depression common (25-50%); often undertreated
• Treat aggressively; improves quality of life and possibly survival

---

SECTION 11: Prognosis

11.1 Natural History

Episode Duration:

• Untreated episode: Median 6-9 months; 10-20% become chronic (> 2 years)
• Treated episode: Response typically by 4-6 weeks; remission by 8-12 weeks

Recurrence:

• After 1 episode: 50% recurrence risk
• After 2 episodes: 70-80% recurrence risk
• After 3 episodes: 90% recurrence risk [6]

Chronicity:

• 15-20% have chronic course (continuous or minimal remission)
• Risk factors: Early onset, severity, comorbidity, inadequate treatment

11.2 Prognostic Factors

Favorable Prognosis:

• Acute onset
• Identifiable precipitant
• Good premorbid functioning
• Strong social support
• Full inter-episode recovery
• Treatment adherence
• Single episode

Poor Prognosis:

• Insidious onset
• Chronic course
• Comorbid personality disorder
• Comorbid substance use
• Residual symptoms
• Multiple prior episodes
• Early onset
• Psychotic features (higher recurrence)

11.3 Mortality

Suicide:

• Lifetime mortality: 4-7% in hospitalized patients; 2-4% in outpatients [7]
• 15-25% of patients with recurrent MDD will attempt suicide

All-Cause Mortality:

• Depression associated with 1.8x increased all-cause mortality
• Cardiovascular mortality increased 1.5-2x
• Mechanisms: Behavioral (smoking, inactivity, non-adherence), biological (inflammation, HPA dysregulation)

---

SECTION 12: Complications

12.1 Psychiatric Complications

12.2 Medical Complications

12.3 Treatment Complications

---

SECTION 13: Evidence and Guidelines

13.1 Major Guidelines

NICE NG222 (2022) - Depression in Adults: [5]

• Key recommendations:
  • Shared decision-making regarding treatment choice
  • "For mild: Active monitoring, low-intensity interventions, physical activity"
  • "For moderate-severe: Combination of antidepressant + high-intensity psychological therapy"
  • Antidepressant choice based on side effect profile and patient preference
  • Continuation treatment for 6+ months after remission
  • Gradual withdrawal when discontinuing

APA Practice Guideline (2010, updated 2019): [12]

• Pharmacotherapy or evidence-based psychotherapy as initial treatment
• Combined treatment for moderate-severe or chronic depression
• Sequential treatment strategies for inadequate response
• Maintenance treatment for recurrent depression

CANMAT Guidelines (2016, updated 2023):

• First-line: SSRIs, SNRIs, bupropion, mirtazapine
• Second-line: TCAs, trazodone, MAOIs
• Adjunctive: Aripiprazole, quetiapine, lithium

13.2 Landmark Trials

STAR*D (Sequenced Treatment Alternatives to Relieve Depression) - 2006 [11]

• Design: Large-scale, multi-step, pragmatic trial (n=3,671)
• Question: What is the effectiveness of sequenced treatments in real-world patients?
• Key Findings:
  • "Level 1 (Citalopram): 33% remission"
  • "Cumulative remission after 4 steps: 67%"
  • Each subsequent step had lower remission rates
  • Augmentation and switching equally effective
• Impact: Established evidence for sequential treatment strategies; showed need for multiple trials

Cipriani et al. Lancet Meta-Analysis - 2018 [4]

• Design: Network meta-analysis of 522 RCTs (116,477 participants)
• Question: Comparative efficacy and acceptability of 21 antidepressants
• Key Findings:
  • All 21 antidepressants more effective than placebo
  • "Most effective: Amitriptyline, mirtazapine, venlafaxine"
  • "Most tolerable: Agomelatine, citalopram, escitalopram, fluoxetine"
  • "Best balance: Escitalopram, sertraline"
• Impact: Definitive evidence that antidepressants work; guides drug selection

SADHART (Sertraline Antidepressant Heart Attack Randomized Trial) - 2002

• Design: RCT of sertraline vs. placebo in post-MI depression (n=369)
• Key Finding: Sertraline safe and effective post-MI
• Impact: Established SSRI safety in cardiovascular disease

UK ECT Review Group Cochrane Review - 2019 [13]

• Design: Systematic review and meta-analysis
• Key Finding: ECT superior to sham ECT and pharmacotherapy for depression
• Impact: Confirms ECT efficacy; gold standard for severe/TRD

PANDA Trial - 2019

• Design: Primary care RCT of sertraline vs. placebo (n=655)
• Key Findings: Sertraline improved anxiety symptoms by 6 weeks; depression improvement by 12 weeks
• Impact: Supports SSRI use in primary care; highlights early anxiety improvement

---

SECTION 14: Examination Focus

14.1 High-Yield Examination Topics

14.2 Sample Examination Questions

Question 1 (MRCP Style): A 68-year-old man presents with 6 weeks of low mood, poor concentration, and memory difficulties. He repeatedly answers "I don't know" to cognitive testing questions. His wife reports he no longer enjoys gardening.

What is the most likely diagnosis?

• A) Alzheimer's disease
• B) Major depressive disorder with pseudodementia
• C) Vascular dementia
• D) Frontotemporal dementia
• E) Lewy body dementia

Answer: B. "I don't know" responses with subjective distress about deficits and anhedonia are characteristic of depressive pseudodementia. Dementia typically shows confabulation and lack of insight.

Question 2 (USMLE Style): A 32-year-old woman with MDD on sertraline 100mg reports improvement in mood but persistent sexual dysfunction and emotional blunting. Which medication would be most appropriate to add?

• A) Lithium
• B) Bupropion
• C) Aripiprazole
• D) Mirtazapine
• E) Increase sertraline

Answer: B. Bupropion (NE/DA mechanism, no sexual side effects) can counteract SSRI-induced sexual dysfunction.

Question 3 (MRCPsych Style): Which feature would most strongly suggest electroconvulsive therapy as first-line treatment for major depressive disorder?

• A) Comorbid anxiety disorder
• B) First episode of depression
• C) Nihilistic delusions
• D) Atypical features
• E) Poor response to one SSRI

Answer: C. Psychotic features (including nihilistic delusions) are an indication for ECT as first-line treatment.

---

SECTION 15: References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013. ISBN: 978-0-89042-555-8

2. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. PMID: 28315433

3. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-2312. PMID: 30396512

4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. PMID: 29477251

5. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline [NG222]. 2022. https://www.nice.org.uk/guidance/ng222

6. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-1006. PMID: 10401442

7. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry. 2000;157(12):1925-1932. PMID: 11097952

8. National Institute of Mental Health. Major Depression. Statistics. 2020. https://www.nimh.nih.gov/health/statistics/major-depression

9. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-138. PMID: 23514317

10. Lim GY, Tam WW, Lu Y, et al. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. PMID: 29434331

11. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PMID: 17074942

12. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. Am J Psychiatry. 2010;167(10 Suppl):1-152. PMID: 21890579

13. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799-808. PMID: 12642045

14. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. PMID: 11556941

15. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1-7. PMID: 24314926

16. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338-343. PMID: 15265848

17. Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171(10):1067-1073. PMID: 24935197

18. Koenig AM, Bhalla RK, Butters MA. Cognitive functioning and late-life depression. J Int Neuropsychol Soc. 2014;20(5):461-467. PMID: 24685173

19. Simon RI. Suicide risk assessment: Gateway to treatment and management. In: Simon RI, Hales RE, eds. Textbook of Suicide Assessment and Management. 2nd ed. American Psychiatric Publishing; 2012:3-28.

20. Santomauro DF, Mantilla Herrera AM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700-1712. PMID: 34634250

21. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. PMID: 26711676

22. Jacka FN, O'Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15(1):23. PMID: 28137247

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines. Emergency presentations require immediate clinical assessment.